Vaxart, Inc. (VXRT)
USD 0.34
(-10.23%)
USD 0.34
(-10.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 34.02 Million USD | -21.33% |
| 2022 | 43.25 Million USD | 28.58% |
| 2021 | 33.63 Million USD | 15.28% |
| 2020 | 29.17 Million USD | 21.17% |
| 2019 | 24.08 Million USD | 0.38% |
| 2018 | 23.98 Million USD | -44.53% |
| 2017 | 43.24 Million USD | 102.08% |
| 2016 | 21.4 Million USD | -19.25% |
| 2015 | 26.5 Million USD | 167.68% |
| 2014 | 9.9 Million USD | -63.47% |
| 2013 | 27.1 Million USD | 52.25% |
| 2012 | 17.8 Million USD | -54.47% |
| 2011 | 39.09 Million USD | -26.65% |
| 2010 | 53.3 Million USD | 57.18% |
| 2009 | 33.91 Million USD | 48.47% |
| 2008 | 22.83 Million USD | -75.19% |
| 2007 | 92.03 Million USD | -40.42% |
| 2006 | 154.48 Million USD | -7.77% |
| 2005 | 167.5 Million USD | 99.77% |
| 2004 | 83.85 Million USD | 23.34% |
| 2003 | 67.98 Million USD | 55.26% |
| 2002 | 43.78 Million USD | -64.43% |
| 2001 | 123.1 Million USD | -16.31% |
| 2000 | 147.09 Million USD | -5.95% |
| 1999 | 156.4 Million USD | -4.69% |
| 1998 | 164.1 Million USD | 9.25% |
| 1997 | 150.2 Million USD | 29.48% |
| 1996 | 116 Million USD | 69.1% |
| 1995 | 68.6 Million USD | 63.33% |
| 1994 | 42 Million USD | 20.34% |
| 1993 | 34.9 Million USD | 3.87% |
| 1992 | 33.6 Million USD | 192.17% |
| 1991 | 11.5 Million USD | -0.86% |
| 1990 | 11.6 Million USD | -21.09% |
| 1989 | 14.7 Million USD | 16.67% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 33.73 Million USD | 2.29% |
| 2024 Q1 | 32.97 Million USD | -3.07% |
| 2023 Q1 | 40.09 Million USD | -7.29% |
| 2023 Q2 | 37.58 Million USD | -6.28% |
| 2023 Q3 | 34.12 Million USD | -9.2% |
| 2023 Q4 | 34.02 Million USD | -0.28% |
| 2023 FY | 34.02 Million USD | -21.33% |
| 2022 Q3 | 53 Million USD | 38.17% |
| 2022 Q4 | 43.25 Million USD | -18.4% |
| 2022 Q1 | 34.01 Million USD | 1.12% |
| 2022 FY | 43.25 Million USD | 28.58% |
| 2022 Q2 | 38.36 Million USD | 12.78% |
| 2021 Q4 | 33.63 Million USD | -7.05% |
| 2021 FY | 33.63 Million USD | 15.28% |
| 2021 Q2 | 29.06 Million USD | -1.92% |
| 2021 Q1 | 29.63 Million USD | 1.55% |
| 2021 Q3 | 36.18 Million USD | 24.52% |
| 2020 FY | 29.17 Million USD | 21.17% |
| 2020 Q3 | 23.03 Million USD | -3.85% |
| 2020 Q2 | 23.95 Million USD | 12.62% |
| 2020 Q4 | 29.17 Million USD | 26.68% |
| 2020 Q1 | 21.27 Million USD | -11.67% |
| 2019 FY | 24.08 Million USD | 0.38% |
| 2019 Q1 | 23.73 Million USD | -1.07% |
| 2019 Q2 | 21.4 Million USD | -9.81% |
| 2019 Q4 | 24.08 Million USD | 1.21% |
| 2019 Q3 | 23.79 Million USD | 11.15% |
| 2018 Q3 | 24.64 Million USD | -2.98% |
| 2018 Q1 | 25.43 Million USD | 16.66% |
| 2018 FY | 23.98 Million USD | -44.53% |
| 2018 Q4 | 23.98 Million USD | -2.67% |
| 2018 Q2 | 25.4 Million USD | -0.1% |
| 2017 Q1 | 22.5 Million USD | -21.05% |
| 2017 Q4 | 21.8 Million USD | 4.81% |
| 2017 FY | 43.24 Million USD | 102.08% |
| 2017 Q3 | 20.8 Million USD | -2.8% |
| 2017 Q2 | 21.4 Million USD | -4.89% |
| 2016 Q2 | 26.5 Million USD | 188.04% |
| 2016 FY | 21.4 Million USD | -19.25% |
| 2016 Q3 | 26.5 Million USD | 0.0% |
| 2016 Q1 | 9.2 Million USD | 37.31% |
| 2016 Q4 | 28.5 Million USD | 7.55% |
| 2015 FY | 26.5 Million USD | 167.68% |
| 2015 Q4 | 6.7 Million USD | -10.67% |
| 2015 Q3 | 7.5 Million USD | -24.24% |
| 2015 Q2 | 9.9 Million USD | 35.62% |
| 2015 Q1 | 7.3 Million USD | -33.64% |
| 2014 Q1 | 24.5 Million USD | 32.43% |
| 2014 Q2 | 27.1 Million USD | 10.61% |
| 2014 FY | 9.9 Million USD | -63.47% |
| 2014 Q4 | 11 Million USD | -43.3% |
| 2014 Q3 | 19.4 Million USD | -28.41% |
| 2013 Q3 | 14.1 Million USD | -20.79% |
| 2013 FY | 27.1 Million USD | 52.25% |
| 2013 Q4 | 18.5 Million USD | 31.21% |
| 2013 Q2 | 17.8 Million USD | 20.8% |
| 2013 Q1 | 14.73 Million USD | -14.43% |
| 2012 Q2 | 35.61 Million USD | -0.59% |
| 2012 Q3 | 36.54 Million USD | 2.61% |
| 2012 Q4 | 17.22 Million USD | -52.88% |
| 2012 FY | 17.8 Million USD | -54.47% |
| 2012 Q1 | 35.82 Million USD | -8.36% |
| 2011 Q1 | 47.52 Million USD | -10.83% |
| 2011 Q2 | 45.64 Million USD | -3.97% |
| 2011 Q3 | 43.36 Million USD | -4.99% |
| 2011 Q4 | 39.09 Million USD | -9.85% |
| 2011 FY | 39.09 Million USD | -26.65% |
| 2010 FY | 53.3 Million USD | 57.18% |
| 2010 Q1 | 68.74 Million USD | 102.74% |
| 2010 Q2 | 60.66 Million USD | -11.76% |
| 2010 Q4 | 53.3 Million USD | -4.5% |
| 2010 Q3 | 55.81 Million USD | -8.0% |
| 2009 Q3 | 12.54 Million USD | 4.45% |
| 2009 Q1 | 22.49 Million USD | -1.52% |
| 2009 Q2 | 12.01 Million USD | -46.59% |
| 2009 Q4 | 33.91 Million USD | 170.26% |
| 2009 FY | 33.91 Million USD | 48.47% |
| 2008 FY | 22.83 Million USD | -75.19% |
| 2008 Q2 | 50.4 Million USD | -43.89% |
| 2008 Q3 | 43.35 Million USD | -13.99% |
| 2008 Q1 | 89.82 Million USD | -2.41% |
| 2008 Q4 | 22.83 Million USD | -47.31% |
| 2007 Q4 | 92.03 Million USD | -34.59% |
| 2007 FY | 92.03 Million USD | -40.42% |
| 2007 Q3 | 140.7 Million USD | 4.38% |
| 2007 Q2 | 134.79 Million USD | -2.45% |
| 2007 Q1 | 138.18 Million USD | -10.56% |
| 2006 Q3 | 164.57 Million USD | 4.48% |
| 2006 FY | 154.48 Million USD | -7.77% |
| 2006 Q1 | 158.55 Million USD | -5.35% |
| 2006 Q2 | 157.51 Million USD | -0.65% |
| 2006 Q4 | 154.48 Million USD | -6.13% |
| 2005 Q1 | 60.63 Million USD | -27.69% |
| 2005 Q4 | 167.5 Million USD | -6.28% |
| 2005 Q3 | 178.72 Million USD | -1.53% |
| 2005 Q2 | 181.49 Million USD | 199.33% |
| 2005 FY | 167.5 Million USD | 99.77% |
| 2004 Q4 | 83.85 Million USD | 7.17% |
| 2004 FY | 83.85 Million USD | 23.34% |
| 2004 Q1 | 65.24 Million USD | -4.03% |
| 2004 Q2 | 80.56 Million USD | 23.49% |
| 2004 Q3 | 78.24 Million USD | -2.89% |
| 2003 Q2 | 43.1 Million USD | 19.25% |
| 2003 Q4 | 67.98 Million USD | -10.5% |
| 2003 FY | 67.98 Million USD | 55.26% |
| 2003 Q1 | 36.14 Million USD | -17.46% |
| 2003 Q3 | 75.96 Million USD | 76.24% |
| 2002 FY | 43.78 Million USD | -64.43% |
| 2002 Q1 | 108.97 Million USD | -11.47% |
| 2002 Q2 | 33.95 Million USD | -68.84% |
| 2002 Q3 | 33.9 Million USD | -0.17% |
| 2002 Q4 | 43.78 Million USD | 29.17% |
| 2001 Q4 | 123.1 Million USD | 5.96% |
| 2001 Q3 | 116.17 Million USD | -16.69% |
| 2001 Q2 | 139.44 Million USD | 1.25% |
| 2001 Q1 | 137.73 Million USD | -6.37% |
| 2001 FY | 123.1 Million USD | -16.31% |
| 2000 FY | 147.09 Million USD | -5.95% |
| 2000 Q4 | 147.09 Million USD | 5.33% |
| 2000 Q1 | 142.15 Million USD | -9.11% |
| 2000 Q3 | 139.64 Million USD | -6.56% |
| 2000 Q2 | 149.44 Million USD | 5.13% |
| 1999 Q1 | 156.1 Million USD | -4.88% |
| 1999 Q3 | 147 Million USD | -0.47% |
| 1999 Q4 | 156.4 Million USD | 6.39% |
| 1999 FY | 156.4 Million USD | -4.69% |
| 1999 Q2 | 147.7 Million USD | -5.38% |
| 1998 FY | 164.1 Million USD | 9.25% |
| 1998 Q1 | 150.6 Million USD | 0.27% |
| 1998 Q2 | 142.5 Million USD | -5.38% |
| 1998 Q3 | 142.6 Million USD | 0.07% |
| 1998 Q4 | 164.1 Million USD | 15.08% |
| 1997 FY | 150.2 Million USD | 29.48% |
| 1997 Q4 | 150.2 Million USD | 5.7% |
| 1997 Q3 | 142.1 Million USD | 15.53% |
| 1997 Q2 | 123 Million USD | 2.67% |
| 1997 Q1 | 119.8 Million USD | 3.28% |
| 1996 Q1 | 113.5 Million USD | 65.45% |
| 1996 Q2 | 113.2 Million USD | -0.26% |
| 1996 Q3 | 116.3 Million USD | 2.74% |
| 1996 Q4 | 116 Million USD | -0.26% |
| 1996 FY | 116 Million USD | 69.1% |
| 1995 Q3 | 57.4 Million USD | 19.33% |
| 1995 Q4 | 68.6 Million USD | 19.51% |
| 1995 FY | 68.6 Million USD | 63.33% |
| 1995 Q1 | 41.9 Million USD | -0.24% |
| 1995 Q2 | 48.1 Million USD | 14.8% |
| 1994 Q4 | 42 Million USD | -16.0% |
| 1994 FY | 42 Million USD | 20.34% |
| 1994 Q1 | 45.9 Million USD | 31.52% |
| 1994 Q2 | 47.8 Million USD | 4.14% |
| 1994 Q3 | 50 Million USD | 4.6% |
| 1993 Q4 | 34.9 Million USD | -4.12% |
| 1993 Q1 | 32.4 Million USD | -3.57% |
| 1993 Q2 | 34.2 Million USD | 5.56% |
| 1993 FY | 34.9 Million USD | 3.87% |
| 1993 Q3 | 36.4 Million USD | 6.43% |
| 1992 Q1 | 30.1 Million USD | 161.74% |
| 1992 Q2 | 30.8 Million USD | 2.33% |
| 1992 Q3 | 33.2 Million USD | 7.79% |
| 1992 Q4 | 33.6 Million USD | 1.2% |
| 1992 FY | 33.6 Million USD | 192.17% |
| 1991 FY | 11.5 Million USD | -0.86% |
| 1991 Q2 | 8.3 Million USD | -9.78% |
| 1991 Q3 | 12.9 Million USD | 55.42% |
| 1991 Q4 | 11.5 Million USD | -10.85% |
| 1991 Q1 | 9.2 Million USD | -20.69% |
| 1990 Q3 | 14.5 Million USD | 9.02% |
| 1990 Q1 | 13.6 Million USD | -7.48% |
| 1990 Q2 | 13.3 Million USD | -2.21% |
| 1990 FY | 11.6 Million USD | -21.09% |
| 1990 Q4 | 11.6 Million USD | -20.0% |
| 1989 Q4 | 14.7 Million USD | 7.3% |
| 1989 Q3 | 13.7 Million USD | 10.48% |
| 1989 Q2 | 12.4 Million USD | 0.0% |
| 1989 FY | 14.7 Million USD | 16.67% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 89.867% |
| Alkermes plc | 933.53 Million USD | 96.355% |
| Agenus Inc. | 462.29 Million USD | 92.64% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.16% |
| Aptorum Group Limited | 5.25 Million USD | -547.265% |
| Ardelyx, Inc. | 130.76 Million USD | 73.98% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 92.888% |
| Bicycle Therapeutics plc | 224.41 Million USD | 84.838% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 73.869% |
| ChromaDex Corporation | 26.5 Million USD | -28.357% |
| Chimerix, Inc. | 19.74 Million USD | -72.322% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | 3.275% |
| Caribou Biosciences, Inc. | 72.56 Million USD | 53.112% |
| CRISPR Therapeutics AG | 346.76 Million USD | 90.188% |
| Precision BioSciences, Inc. | 140.92 Million USD | 75.855% |
| Dyadic International, Inc. | 2.34 Million USD | -1353.655% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -109.217% |
| Fortress Biotech, Inc. | 165.93 Million USD | 79.495% |
| Lantern Pharma Inc. | 2.73 Million USD | -1141.932% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | 52.399% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -864.229% |
| Incyte Corporation | 1.59 Billion USD | 97.863% |
| IO Biotech, Inc. | 17.55 Million USD | -93.808% |
| Jaguar Health, Inc. | 45.86 Million USD | 25.817% |
| Novavax, Inc. | 2.57 Billion USD | 98.677% |
| Janux Therapeutics, Inc. | 36.05 Million USD | 5.638% |
| Opthea Limited | 264.6 Million USD | 87.141% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 73.968% |
| ContextLogic Inc. | 206 Million USD | 83.483% |
| MiMedx Group, Inc. | 96.33 Million USD | 64.679% |
| Pyxis Oncology, Inc. | 48.02 Million USD | 29.147% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -864.185% |
| NextCure, Inc. | 14.99 Million USD | -126.879% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -741.786% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -409.585% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | 27.202% |
| Vaxcyte, Inc. | 167.44 Million USD | 79.68% |
| PDS Biotechnology Corporation | 33.25 Million USD | -2.303% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 85.534% |
| Pharming Group N.V. | 244.07 Million USD | 86.059% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -185.397% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 73.374% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -414.962% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -414.962% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 58.724% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -412.193% |
| Acelyrin, Inc. | 86.35 Million USD | 60.598% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -2518.837% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -136.63% |
| Summit Therapeutics Inc. | 125.25 Million USD | 72.836% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -258.951% |
| Senti Biosciences, Inc. | 52.57 Million USD | 35.278% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | 50.529% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 77.543% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -1639.519% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -2447.613% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 85.0% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -263.243% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 85.04% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 93.119% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -211.756% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -23.678% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -181.089% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 93.008% |
| Immix Biopharma, Inc. | 3.72 Million USD | -814.212% |
| Keros Therapeutics, Inc. | 37.81 Million USD | 10.015% |
| MEI Pharma, Inc. | 8.35 Million USD | -307.241% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -17.267% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 90.211% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 76.674% |
| Fortress Biotech, Inc. | 165.93 Million USD | 79.495% |
| Precigen, Inc. | 41.64 Million USD | 18.296% |
| Clearside Biomedical, Inc. | 49.93 Million USD | 31.855% |
| AlloVir, Inc. | 45.01 Million USD | 24.414% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 73.895% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 75.308% |
| ImmuCell Corporation | 18.81 Million USD | -80.84% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -20.545% |
| Onconetix, Inc. | 23.18 Million USD | -46.78% |
| PureTech Health plc | 125.58 Million USD | 72.906% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -280.168% |
| Elevation Oncology, Inc. | 34.28 Million USD | 0.75% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -1291.616% |
| Seer, Inc. | 39.36 Million USD | 13.565% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | 44.974% |
| Innoviva, Inc. | 568.55 Million USD | 94.015% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -24.963% |
| ESSA Pharma Inc. | 3.49 Million USD | -873.514% |
| GlycoMimetics, Inc. | 6.9 Million USD | -392.968% |
| GT Biopharma, Inc. | 6.63 Million USD | -412.965% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 87.131% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 87.504% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 59.507% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -248.117% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -25.235% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -954.786% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | 53.875% |
| Aptose Biosciences Inc. | 15.8 Million USD | -115.23% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -208.206% |
| Soligenix, Inc. | 7.27 Million USD | -367.704% |
| Century Therapeutics, Inc. | 175.94 Million USD | 80.661% |
| Kura Oncology, Inc. | 51.66 Million USD | 34.139% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 71.946% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -723.252% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -414.45% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 86.53% |
| Autolus Therapeutics plc | 263.9 Million USD | 87.107% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -224.604% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 61.71% |
| Eterna Therapeutics Inc. | 46.89 Million USD | 27.45% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 90.357% |
| GRI Bio, Inc. | 2.69 Million USD | -1161.587% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -4102.771% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -9.437% |
| IGM Biosciences, Inc. | 220.17 Million USD | 84.547% |
| INmune Bio, Inc. | 18.86 Million USD | -80.389% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 86.734% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -27.713% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -1151.653% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -937.263% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | 41.793% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 64.616% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 87.148% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 95.866% |
| Verastem, Inc. | 71.18 Million USD | 52.202% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 30.81% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | 11.802% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | 30.465% |
| Histogen Inc. | 5.69 Million USD | -497.244% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -675.834% |
| Surrozen, Inc. | 8.14 Million USD | -317.741% |
| Organovo Holdings, Inc. | 2.74 Million USD | -1138.173% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -10740.89% |
| Ovid Therapeutics Inc. | 56.22 Million USD | 39.489% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -106.062% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | 33.419% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -4014.89% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 73.151% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -214.65% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 77.45% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -1204.967% |
| Apollomics, Inc. | 14.15 Million USD | -140.408% |
| Amarin Corporation plc | 279.58 Million USD | 87.83% |
| Mesoblast Limited | 188.79 Million USD | 81.978% |
| Turnstone Biologics Corp. | 14.14 Million USD | -140.493% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 81.18% |
| Synaptogenix, Inc. | 5.52 Million USD | -515.339% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -411.808% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 79.998% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -297.619% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -1836.106% |
| Exelixis, Inc. | 678.44 Million USD | 94.985% |
| Better Therapeutics, Inc. | 23.84 Million USD | -42.71% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 79.259% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 94.274% |
| NLS Pharmaceutics AG | 10.68 Million USD | -218.58% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -1995.631% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 12.593% |
| Gritstone bio, Inc. | 125.91 Million USD | 72.979% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -131.841% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -568.648% |
| Avid Bioservices, Inc. | 275.66 Million USD | 87.657% |
| Insmed Incorporated | 1.66 Billion USD | 97.952% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -342.226% |
| MediWound Ltd. | 27.18 Million USD | -25.152% |
| OmniAb, Inc. | 87.4 Million USD | 61.07% |
| Alector, Inc. | 487.66 Million USD | 93.023% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 91.567% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -84.668% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 11.331% |
| Zai Lab Limited | 240.17 Million USD | 85.833% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 94.6% |
| Aura Biosciences, Inc. | 29.22 Million USD | -16.416% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 64.213% |
| Immunic, Inc. | 25.36 Million USD | -34.126% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | 50.856% |
| Veracyte, Inc. | 93.71 Million USD | 63.695% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -1200.315% |
| FibroGen, Inc. | 585.72 Million USD | 94.191% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -95.737% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -5109.96% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -501.631% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 99.556% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -315.04% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 59.505% |
| TG Therapeutics, Inc. | 169.08 Million USD | 79.877% |
| Galecto, Inc. | 5.89 Million USD | -477.086% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -310.732% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 98.701% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -18.052% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -169.59% |
| XBiotech Inc. | 8.39 Million USD | -305.204% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -131.841% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | 36.019% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 90.629% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -26.562% |
| Theravance Biopharma, Inc. | 169 Million USD | 79.867% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 97.201% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 93.201% |
| Vaxxinity, Inc. | 30.94 Million USD | -9.957% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 96.501% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -464.158% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 95.434% |
| NexImmune, Inc. | 5.08 Million USD | -569.226% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -9061.43% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -1006.559% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.521% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -560.163% |
| Scopus BioPharma Inc. | 7.45 Million USD | -356.44% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -29.402% |
| Ainos, Inc. | 7.39 Million USD | -360.157% |
| Pluri Inc. | 34.11 Million USD | 0.255% |
| Prothena Corporation plc | 135.01 Million USD | 74.799% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 86.004% |
| Celularity Inc. | 102.92 Million USD | 66.943% |
| Rallybio Corporation | 9.43 Million USD | -260.587% |
| Cue Biopharma, Inc. | 24.44 Million USD | -39.19% |
| MeiraGTx Holdings plc | 319.99 Million USD | 89.367% |
| Omeros Corporation | 403.25 Million USD | 91.562% |
| Humacyte, Inc. | 114.67 Million USD | 70.33% |
| Immunocore Holdings plc | 228.15 Million USD | 85.087% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -597.949% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | 55.662% |
| Blueprint Medicines Corporation | 918.64 Million USD | 96.296% |
| CalciMedica, Inc. | 4.02 Million USD | -744.712% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -94.963% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 77.926% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 60.352% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 87.752% |
| Pulmatrix, Inc. | 15.96 Million USD | -113.149% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -115.717% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -38.279% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 86.434% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | 33.003% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 97.19% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -7.054% |
| Nutriband Inc. | 1.07 Million USD | -3053.62% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -219.994% |
| Vor Biopharma Inc. | 59.1 Million USD | 42.432% |
| Roivant Sciences Ltd. | 773.95 Million USD | 95.604% |
| Evogene Ltd. | 17.99 Million USD | -89.133% |
| ProKidney Corp. | 29.21 Million USD | -16.46% |
| Applied Therapeutics, Inc. | 71.97 Million USD | 52.729% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -4726.358% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 98.199% |
| CorMedix Inc. | 11.91 Million USD | -185.504% |
| BioLineRx Ltd. | 50.7 Million USD | 32.892% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 77.235% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 61.528% |
| Atai Life Sciences N.V. | 49.16 Million USD | 30.79% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -9.221% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -89.428% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 72.701% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -501.786% |
| MediciNova, Inc. | 3.89 Million USD | -774.33% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -86.143% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -2161.938% |
| GeoVax Labs, Inc. | 3.51 Million USD | -866.652% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 91.435% |
| Biomea Fusion, Inc. | 30.69 Million USD | -10.867% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 98.75% |
| Mereo BioPharma Group plc | 15.96 Million USD | -113.163% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -9.051% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | 42.02% |
| Absci Corporation | 58.3 Million USD | 41.642% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -78.628% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -6.123% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | 53.889% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 61.107% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -0.755% |
| Allakos Inc. | 74.79 Million USD | 54.508% |
| Imunon, Inc. | 8.53 Million USD | -298.866% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -51.216% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 70.365% |
| BioAtla, Inc. | 48.98 Million USD | 30.541% |
| NLS Pharmaceutics AG | 10.68 Million USD | -218.58% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1124.361% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 73.948% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -139.36% |
| XOMA Corporation | 145.58 Million USD | 76.628% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -1.069% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 50.516% |
| aTyr Pharma, Inc. | 31.59 Million USD | -7.684% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | 44.964% |
| Akero Therapeutics, Inc. | 44.96 Million USD | 24.33% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | 29.703% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -1085.54% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -317.074% |
| Akari Therapeutics, Plc | 4.58 Million USD | -642.256% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -91.873% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.937% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -8323.948% |
| UroGen Pharma Ltd. | 243.52 Million USD | 86.028% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 89.403% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1132.094% |
| Orgenesis Inc. | 35.53 Million USD | 4.249% |
| Entera Bio Ltd. | 1.37 Million USD | -2367.368% |
| GH Research PLC | 6.7 Million USD | -407.76% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -400.368% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -80.734% |
| Xencor, Inc. | 283.55 Million USD | 88.001% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -1039.608% |
| Replimune Group, Inc. | 113.21 Million USD | 69.946% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -805.613% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 67.135% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -8323.948% |
| Portage Biotech Inc. | 4.45 Million USD | -664.607% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -2161.938% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -47.614% |
| OncoCyte Corporation | 49.29 Million USD | 30.981% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -722.495% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -4166.543% |
| Purple Biotech Ltd. | 10 Million USD | -240.08% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -488.057% |
| scPharmaceuticals Inc. | 57.26 Million USD | 40.579% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -174.66% |
| HilleVax, Inc. | 78.9 Million USD | 56.881% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -573.762% |
| Tharimmune, Inc. | 1.81 Million USD | -1774.608% |
| Genprex, Inc. | 3.25 Million USD | -945.569% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -25.466% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -549.828% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -16416.99% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -9389.664% |
| OKYO Pharma Limited | 7.42 Million USD | -358.506% |
| Savara Inc. | 37.19 Million USD | 8.515% |
| Curis, Inc. | 57.61 Million USD | 40.941% |
| Daré Bioscience, Inc. | 26.32 Million USD | -29.226% |
| Carmell Therapeutics Corporation | 39.19 Million USD | 13.201% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -2256.302% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -63.432% |
| BeiGene, Ltd. | 2.23 Billion USD | 98.477% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -59.818% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 87.033% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -59.937% |
| Erasca, Inc. | 78.61 Million USD | 56.717% |
| bluebird bio, Inc. | 424.62 Million USD | 91.987% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -5092.659% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 98.2% |
| DBV Technologies S.A. | 42.8 Million USD | 20.502% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -5092.659% |
| Moderna, Inc. | 4.57 Billion USD | 99.256% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -386.419% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -1954.65% |
| Molecular Templates, Inc. | 31.17 Million USD | -9.156% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -99.326% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 94.214% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 72.672% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -24.011% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | 6.668% |
| Cogent Biosciences, Inc. | 55.63 Million USD | 38.842% |
| MacroGenics, Inc. | 154.2 Million USD | 77.936% |
| RenovoRx, Inc. | 4.46 Million USD | -661.867% |
| Adicet Bio, Inc. | 37.12 Million USD | 8.338% |
| Prime Medicine, Inc. | 60.78 Million USD | 44.019% |
| Aditxt, Inc. | 28.53 Million USD | -19.254% |
| Adagene Inc. | 45.16 Million USD | 24.672% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -18729.448% |
| Quantum-Si incorporated | 26.63 Million USD | -27.765% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 95.122% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -1018.347% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 70.403% |
| SciSparc Ltd. | 1.59 Million USD | -2033.229% |
| Vericel Corporation | 127.7 Million USD | 73.357% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -511.422% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 60.139% |
| Generation Bio Co. | 171.63 Million USD | 80.175% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -194.589% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | 18.661% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 86.535% |
| Invivyd, Inc. | 51.71 Million USD | 34.204% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 63.007% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -423.039% |
| Spero Therapeutics, Inc. | 75.49 Million USD | 54.931% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -3232.517% |
| 2seventy bio, Inc. | 310.12 Million USD | 89.029% |
| ADMA Biologics, Inc. | 193.97 Million USD | 82.459% |
| Clene Inc. | 38.95 Million USD | 12.647% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | 5.834% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 86.759% |
| GeoVax Labs, Inc. | 3.51 Million USD | -866.652% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 82.117% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -179.359% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 82.844% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -179.012% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 29.278% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | 35.609% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 90.8% |
| Evaxion Biotech A/S | 17.61 Million USD | -93.132% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 78.857% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 77.788% |
| Trevena, Inc. | 48.26 Million USD | 29.499% |
| Surrozen, Inc. | 8.14 Million USD | -317.741% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -57.56% |
| Cingulate Inc. | 10.36 Million USD | -228.399% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -1137.273% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 8.761% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -848.691% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -158.745% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 89.273% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -36.927% |
| Clearmind Medicine Inc. | 3.61 Million USD | -842.519% |
| Kronos Bio, Inc. | 54.2 Million USD | 37.224% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | 27.673% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -49.496% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -69.523% |
| Statera Biopharma, Inc. | 22.67 Million USD | -50.046% |
| ImmunityBio, Inc. | 1.09 Billion USD | 96.88% |
| Korro Bio, Inc. | 51.75 Million USD | 34.254% |
| Kineta, Inc. | 7.22 Million USD | -371.13% |
| BioVie Inc. | 9.7 Million USD | -250.696% |
| Codexis, Inc. | 49.94 Million USD | 31.876% |
| Celularity Inc. | 102.92 Million USD | 66.943% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 64.648% |
| Celcuity Inc. | 51.45 Million USD | 33.868% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -9756.776% |
| Cibus, Inc. | 206.11 Million USD | 83.492% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | 19.894% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -29.181% |
| IN8bio, Inc. | 8.77 Million USD | -287.882% |
| Kodiak Sciences Inc. | 213.59 Million USD | 84.07% |
| Annexon, Inc. | 47.11 Million USD | 27.788% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 62.001% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 64.694% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -148.557% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.693% |
| Eyenovia, Inc. | 19.78 Million USD | -72.015% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 80.786% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -342.976% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -41.188% |
| Arcellx, Inc. | 339.75 Million USD | 89.985% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -185.972% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 86.143% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -255.798% |
| Moolec Science SA | 13.94 Million USD | -143.988% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | 21.151% |
| Geron Corporation | 146.12 Million USD | 76.715% |
| LAVA Therapeutics N.V. | 50.53 Million USD | 32.666% |
| Royalty Pharma plc | 6.29 Billion USD | 99.46% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | 14.458% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -11457.169% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -1282.972% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 82.012% |
| Humacyte, Inc. | 114.67 Million USD | 70.33% |
| Structure Therapeutics Inc. | 29.05 Million USD | -17.122% |
| 89bio, Inc. | 59.96 Million USD | 43.257% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -28.576% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -2744.9% |
| Genelux Corporation | 8.42 Million USD | -304.097% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -396.281% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 75.04% |
| Notable Labs, Ltd. | 4.42 Million USD | -668.579% |
| Liquidia Corporation | 73.13 Million USD | 53.478% |
| Mustang Bio, Inc. | 17.61 Million USD | -93.115% |
| Immunovant, Inc. | 48.95 Million USD | 30.497% |
| Quantum-Si incorporated | 26.63 Million USD | -27.765% |
| Arbutus Biopharma Corporation | 38.38 Million USD | 11.354% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -996.519% |
| Vera Therapeutics, Inc. | 73.86 Million USD | 53.934% |
| Acasti Pharma Inc. | 11.55 Million USD | -194.41% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -50.502% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -1151.653% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | 7.734% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -2396.621% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -458.153% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -37.004% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -46.761% |
| PepGen Inc. | 34.63 Million USD | 1.75% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -180.18% |
| United Therapeutics Corporation | 1.18 Billion USD | 97.122% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -387.185% |
| Solid Biosciences Inc. | 38.45 Million USD | 11.527% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -297.619% |
| Immuneering Corporation | 12 Million USD | -183.344% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -10740.89% |
| Silo Pharma, Inc. | 1.56 Million USD | -2068.206% |
| Belite Bio, Inc | 4.21 Million USD | -708.003% |
| XOMA Corporation | 145.58 Million USD | 76.628% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -1301.359% |
| Bionomics Limited | 10.15 Million USD | -234.934% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -58.322% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -48.496% |
| uniQure N.V. | 624.01 Million USD | 94.547% |
| Cassava Sciences, Inc. | 14.19 Million USD | -139.697% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -18729.448% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 80.007% |
| Forte Biosciences, Inc. | 3.66 Million USD | -828.123% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -12957.26% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -404.298% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -342.976% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -95.737% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -221.963% |
| Altimmune, Inc. | 16.54 Million USD | -105.701% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 94.492% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -48.496% |
| Compugen Ltd. | 55.77 Million USD | 38.996% |
| Peak Bio, Inc. | 20.75 Million USD | -63.949% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 69.198% |
| Benitec Biopharma Inc. | 4.96 Million USD | -585.711% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 78.444% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | 54.738% |
| Zura Bio Limited | 21.29 Million USD | -59.802% |
| PolyPid Ltd. | 17.46 Million USD | -94.785% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 69.728% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | 54.738% |
| Instil Bio, Inc. | 99.8 Million USD | 65.907% |
| argenx SE | 444.95 Million USD | 92.353% |
| Immunome, Inc. | 28.65 Million USD | -18.728% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -308.12% |
| Verona Pharma plc | 58.84 Million USD | 42.175% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -135.093% |
| Shattuck Labs, Inc. | 14.85 Million USD | -128.986% |
| CervoMed Inc. | 2.59 Million USD | -1210.798% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -598.092% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -167.156% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -222.971% |
| Moolec Science SA | 13.94 Million USD | -143.988% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -1351.886% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | 38.799% |
| AnaptysBio, Inc. | 364.28 Million USD | 90.66% |
| Design Therapeutics, Inc. | 11.95 Million USD | -184.585% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -168.251% |
| NeurAxis, Inc. | 1.91 Million USD | -1678.863% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | 12.595% |
| Lumos Pharma, Inc. | 13.33 Million USD | -155.194% |
| Achilles Therapeutics plc | 19.08 Million USD | -78.263% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -135.093% |
| 180 Life Sciences Corp. | 5.38 Million USD | -531.589% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -44.247% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -49.496% |
| Nutriband Inc. | 1.07 Million USD | -3053.62% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -11.2% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -134.477% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 91.521% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -4.779% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -160.746% |
| Palisade Bio, Inc. | 2.73 Million USD | -1142.242% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -547.725% |
| Beam Therapeutics Inc. | 478.38 Million USD | 92.888% |
| Neurogene Inc. | 36.54 Million USD | 6.906% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 91.45% |
| AEON Biopharma, Inc. | 159.88 Million USD | 78.72% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | 28.594% |
| Sesen Bio, Inc. | 30.98 Million USD | -9.815% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -31.062% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -347.567% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 82.617% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 82.284% |
| Athira Pharma, Inc. | 30.05 Million USD | -13.202% |
| Vaccinex, Inc. | 5.94 Million USD | -472.619% |
| HCW Biologics Inc. | 15.05 Million USD | -126.051% |
| XOMA Corporation | 145.58 Million USD | 76.628% |
| Nektar Therapeutics | 267.04 Million USD | 87.259% |
| Arvinas, Inc. | 644.6 Million USD | 94.722% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -91.873% |
| Merus N.V. | 102.15 Million USD | 66.691% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 76.751% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 64.229% |
| Rezolute, Inc. | 11.73 Million USD | -189.969% |
| Clene Inc. | 38.95 Million USD | 12.647% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -1094.958% |
| BeyondSpring Inc. | 48.26 Million USD | 29.51% |
| Synlogic, Inc. | 32.89 Million USD | -3.435% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -132.841% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -1982.313% |
| Peak Bio, Inc. | 20.75 Million USD | -63.949% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | 46.383% |
| Krystal Biotech, Inc. | 39.71 Million USD | 14.325% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 90.966% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 65.828% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -7762.943% |
| MannKind Corporation | 721.36 Million USD | 95.283% |
| Ikena Oncology, Inc. | 22.33 Million USD | -52.339% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -1531.112% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 66.834% |
| Gossamer Bio, Inc. | 249.14 Million USD | 86.343% |
| CohBar, Inc. | 1.03 Million USD | -3191.771% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -218.318% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -78.628% |
| Legend Biotech Corporation | 589.93 Million USD | 94.232% |
| Mural Oncology plc | 37.92 Million USD | 10.291% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 74.347% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1382.356% |
| Disc Medicine, Inc. | 22.87 Million USD | -48.743% |
| Champions Oncology, Inc. | 28.03 Million USD | -21.366% |
| REGENXBIO Inc. | 262.22 Million USD | 87.025% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -912.844% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -171.462% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -153.32% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -60.457% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -66.877% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -19.253% |
| Cellectis S.A. | 249.57 Million USD | 86.367% |
| Longeveron Inc. | 5.33 Million USD | -537.53% |
| Repare Therapeutics Inc. | 41.81 Million USD | 18.637% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.585% |
| Inozyme Pharma, Inc. | 60.36 Million USD | 43.637% |
| Revolution Medicines, Inc. | 262.39 Million USD | 87.033% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -1514.855% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -294.447% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -188.323% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -142.292% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -1481.822% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.339% |
| Denali Therapeutics Inc. | 122.96 Million USD | 72.329% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -511.422% |
| Veru Inc. | 32.81 Million USD | -3.695% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -395.341% |
| Cingulate Inc. | 10.36 Million USD | -228.399% |
| Passage Bio, Inc. | 39.26 Million USD | 13.339% |
| Context Therapeutics Inc. | 4.19 Million USD | -711.72% |
| Exicure, Inc. | 8.54 Million USD | -298.0% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -15.308% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -224.48% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -54.371% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 79.124% |
| Nuvalent, Inc. | 31.82 Million USD | -6.92% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -434.847% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | 46.011% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -89.028% |
| OmniAb, Inc. | 87.4 Million USD | 61.07% |
| Anew Medical, Inc. | 8.24 Million USD | -312.835% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | 11.137% |
| Lipocine Inc. | 2.63 Million USD | -1192.925% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -29.511% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | 15.386% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -27.713% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 60.507% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -529.976% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 58.881% |
| Ocugen, Inc. | 23.98 Million USD | -41.871% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | 26.681% |
| Q32 Bio Inc. | 233.12 Million USD | 85.405% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -275.303% |
| Alumis Inc. Common Stock | 53.5 Million USD | 36.404% |
| Equillium, Inc. | 27.95 Million USD | -21.705% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 83.53% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -504.71% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -454.788% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 78.373% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 50.996% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -241.13% |
| Dominari Holdings Inc. | 4.63 Million USD | -634.088% |
| Edesa Biotech, Inc. | 1.84 Million USD | -1747.541% |
| vTv Therapeutics Inc. | 29.56 Million USD | -15.078% |
| Bio-Techne Corporation | 744.34 Million USD | 95.429% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 73.017% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 90.122% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | 16.143% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -17.502% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 63.16% |
| Nkarta, Inc. | 105.6 Million USD | 67.779% |
| BioCardia, Inc. | 4.59 Million USD | -641.285% |
| Iterum Therapeutics plc | 32.66 Million USD | -4.173% |